



US 20210277150A1

(19) **United States**(12) **Patent Application Publication****Von Kreudenstein et al.**(10) **Pub. No.: US 2021/0277150 A1**(43) **Pub. Date: Sep. 9, 2021**(54) **STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE FC DOMAIN**

provisional application No. 61/425,375, filed on Dec. 21, 2010, provisional application No. 61/410,746, filed on Nov. 5, 2010.

(71) Applicant: **ZYMEWORKS INC.**, Vancouver (CA)(72) Inventors: **Thomas Spreter Von Kreudenstein**, Vancouver (CA); **Eric Escobar-Cabrera**, Burnaby (CA); **Surjit Bhimarao Dixit**, Richmond (CA); **Paula Irene Lario**, Vancouver (CA); **David Kai Yuen Poon**, Richmond (CA); **Igor D'Angelo**, Vancouver (CA)(21) Appl. No.: **17/107,217**(22) Filed: **Nov. 30, 2020****Related U.S. Application Data**

(63) Continuation of application No. 15/409,456, filed on Jan. 18, 2017, now Pat. No. 10,875,931, which is a continuation of application No. 13/289,934, filed on Nov. 4, 2011, now Pat. No. 9,562,109.

(60) Provisional application No. 61/497,861, filed on Jun. 16, 2011, provisional application No. 61/491,846, filed on May 31, 2011, provisional application No. 61/475,614, filed on Apr. 14, 2011, provisional application No. 61/439,341, filed on Feb. 3, 2011,

Publication Classification(51) **Int. Cl.****C07K 16/46** (2006.01)**C07K 16/00** (2006.01)**C07K 16/32** (2006.01)(52) **U.S. Cl.**CPC **C07K 16/468** (2013.01); **C07K 16/00** (2013.01); **C07K 16/32** (2013.01); **C07K 2317/64** (2013.01); **C07K 2317/524** (2013.01); **C07K 2317/526** (2013.01); **C07K 2317/30** (2013.01)

(57)

ABSTRACT

The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.

Specification includes a Sequence Listing.